- 专利标题： Triazolopyrimidine, triazolopyridine compounds, and the composition thereof for treating PRC2-mediated diseases
-
申请号： US16651510申请日： 2018-08-29
-
公开(公告)号： US11013745B2公开(公告)日： 2021-05-25
- 发明人: Bing Zhou , Cheng Luo , Yaxi Yang , Yuanyuan Zhang , Daohai Du , Hualiang Jiang , Gang Qiao , Xinjun Wang
- 申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES , SUZHOU SUPLEAD LIFE SCIENCES CO., LTD.
- 申请人地址： CN Shanghai; CN Jiangsu
- 专利权人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES,SUZHOU SUPLEAD LIFE SCIENCES CO., LTD.
- 当前专利权人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES,SUZHOU SUPLEAD LIFE SCIENCES CO., LTD.
- 当前专利权人地址： CN Shanghai; CN Jiangsu
- 代理机构： Meunier Carlin & Curfman LLC
- 优先权： CN201710898099.5 20170928,CN201711408714.6 20171222
- 国际申请： PCT/CN2018/102833 WO 20180829
- 国际公布： WO2019/062435 WO 20190404
- 主分类号： A61K31/519
- IPC分类号： A61K31/519 ; C07D487/04
摘要：
The present invention provides a compound represented by formula I, pharmaceutically acceptable salts, enantiomers, diastereomers or racemates thereof, the preparation method thereof, the pharmaceutical composition comprising the same, and the use thereof in the preparation of a medicament for treating a disease or condition mediated by EED and/or PRC2. The compound of the present invention can be used treating PRC2-mediated diseases or conditions.
公开/授权文献
信息查询
IPC分类:
